Tetravalent etanercept

Details Tetravalent etanercept Tetravalent etanercept

2007-06-12

2007-06-12

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S402000

Reexamination Certificate

active

10363427

ABSTRACT:
Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5428130 (1995-06-01), Capon et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5861151 (1999-01-01), Aruffo et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 6046310 (2000-04-01), Queen et al.
patent: 6090914 (2000-07-01), Linsley et al.
patent: 6100383 (2000-08-01), Gallatin et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6165476 (2000-12-01), Strom et al.
patent: 6210661 (2001-04-01), Enssle et al.
patent: 6225117 (2001-05-01), Gately et al.
patent: 6225448 (2001-05-01), Tao et al.
patent: 2001/0053539 (2001-12-01), Lauffer et al.
patent: 0464533 (1992-01-01), None
patent: 0770628 (1997-05-01), None
patent: 1148065 (2001-10-01), None
patent: 1148065 (2001-10-01), None
patent: 5-247094 (1993-09-01), None
patent: 6-508989 (1994-10-01), None
patent: 7-502413 (1995-03-01), None
patent: 7-504203 (1996-05-01), None
patent: 9-504030 (1997-04-01), None
patent: 92/16221 (1992-10-01), None
patent: 93/00431 (1993-01-01), None
patent: 93/13210 (1993-07-01), None
patent: 93/16184 (1993-08-01), None
patent: 94/06476 (1994-03-01), None
patent: 95/11303 (1995-04-01), None
patent: 95/34326 (1995-12-01), None
patent: 96/23067 (1996-08-01), None
patent: 96/31229 (1996-10-01), None
patent: 97/03682 (1997-02-01), None
patent: 98/31820 (1998-07-01), None
patent: WO 98/21820 (1998-07-01), None
patent: 99/02552 (1999-01-01), None
patent: 99/35260 (1999-07-01), None
patent: 01/77324 (2001-10-01), None
patent: PCT/KR02/01427 (2002-12-01), None
Toby Cornish et al., “Globular Domains of Agrin are Functional Units That Collaborate to Induce Acetylcholine Receptor Clustering”, Journal of Cell Science, vol. 112, pp. 1213-1223 (1999).
J. Exp. Med. vol. 177, No. 5 (1993) pp. 1439-1450.
J. Immunol. Methods vol. 223, No. 2 (1999) pp. 171-183.
FEBS Lett. vol. 360, No. 1 (1995) pp. 43-46.
English Language Machine Translation JP 5-247094.
F. Sanger et al., “DNA Sequencing with Chain-Terminating Inhibitors”, Proc. Natl. Acad. Sci. USA, vol. 74, No. 12, pp. 5463-5467 (1977).
Daniel J. Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy”, Nature, vol. 337, pp. 525-531 (1989).
Werner LESSLAUER et al., “Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice From Lipopolysaccharide-Induced Lethality”, Eur. J. Immunol., vol. 21, pp. 2883-2886 (1991).
Avi Ashkenazi et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin”, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 10535-10539 (1991).
Karsten Peppel et al., “A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimetric Protein as a Bivalent Anatagonist of TNF Activity”, J. Exp. Med., vol. 174, pp. 1483-1489 (1991).
Kendall M. Mohler et al., “Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists”, The Journal of Immunology, vol. 151, pp. 1548-1561 (1993).
Bernard J. Scallon et al., “Functional Comparisons of Different Tumor Necrosis Factor Receptor/IgG Fusion Proteins”, Cytokine, vol. 7, No. 8, pp. 759-770 (1995).
Katherine Harper et al., “CTLA-4 and CD28 Activated Lymphocyte Molecules are Closely Related in Both Mouse and Human as to Sequence, Message Expression, Gene Structure, and Chromosomal Location”, the Journal of Immunology, vol. 147, pp. 1037-1044 (1991).
Jean-Francois Brunet et al., “A New Member of the Immunoglobulin Superfamily -CTLA-4”, Nature, vol. 328, pp. 267-270 (1987).
Peter S. Linsley et al., “CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7”, J. Exp. Med., vol. 174, pp. 561-569 (1991).
Akira Yamada et al., “Long-Term Acceptance of Major Histrocompatibility complex-Mismatched Cardiac Allograft Induced by a Low Dose of CTLA4lgM Plus FK506”, Microbiol. Immunol., vol. 40, No. 7, pp. 513-518 (1996).
Louis A. Tartaglia et al., “Two TNF Receptors”, Immunology Today, vol. 13, No. 5, pp. 151-153 (1992).
B. Beutler, “Chapter 20: Cachectin/Tumor Necrosis Factor and Lymphotoxin”, Peptide Growth Factor II, Springer-Verlag, Berlin, pp. 39-70 (1990).
Michael J. Eck et al., “The Structure of Human Lymphotoxin (Tumor Necrosis Factor-β) at 1.9-Å Resolution, the Journal of Biological Chemistry”, vol. 267, No. 4, pp. 2119-2122 (1992).
Craig A. Smith et al., “A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins”, Science, vol. 248, pp. 1019-1023 (1990).
Hansruedi Loetscher et al., “Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor”, Cell, vol. 61, pp. 351-359 (1990).
Thomas J. Schall et al., “Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor”, Cell, vol. 61, pp. 361-370 (1990).
Sambrook et al., “Molecular Cloning”, Cold Spring Harbor Laboratory Press, pp. 1.25-1.31, 1.6301.69, and 7.26-7.29, (1989).
Chamow Steven M. and Ashkenazi Avi., “Immunoadhesins: principles and applications”, TIBTECH, vol. 14, pp. 52-60 (1996).
Jostock Thomas et al., “Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses”, Eur. J. Biochem, vol. 268, pp. 160-167 (2001).

Affiliated with

Also associated with

Rating

Tetravalent etanercept does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tetravalent etanercept, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetravalent etanercept will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3841919